8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): June 21, 2005

BOSTON SCIENTIFIC CORPORATION

(Exact name of registrant as specified in charter)

DELAWARE	1-11083	04-2695240
(State or other	(Commission	(IRS employer
jurisdiction of	file number)	identification no.)
incorporation)

One Boston Scientific Place, Natick, Massachusetts	01760-1537
(Address of principal executive offices)	(Zip code)

Registrant’s telephone number, including area code:(508) 650-8000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the fling obligation of the registrant under any of the following provisions:

o Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events.

On June 21, 2005, a jury in Delaware found that Boston Scientific's TAXUS^® Express™, Express™, Express™ Biliary, and Liberté™ stents infringe a Johnson & Johnson patent, and that the Liberté stent infringes a second J&J patent. This suit was originally filed by J&J (through its subsidiary Cordis Corporation) on January 13, 2003 in the U.S. District Court for the District of Delaware. The jury only determined liability; monetary damages will be determined in a later trial. Boston Scientific intends to appeal the decision. A copy of the press release issued by the Company is attached as Exhibit 99.1 to this Report.

Item 9.01. Financial Statements and Exhibits.

99.1 Press Release dated June 21, 2005

SIGNATURE

Pursuant to the requirements of the Securities and Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	BOSTON SCIENTIFIC CORPORATION
Date: June 24, 2005	By:	/s/ Lawrence J. Knopf
		Lawrence J. Knopf
		Vice President and Assistant General Counsel

INDEX TO EXHIBITS

Exhibit
Number	Description
99.1	Press Release dated June 21, 2005

EX-99.1

Exhibit 99.1

NEWS	Boston
FOR IMMEDIATE RELEASE	Scientific
	Boston Scientific Corporation
	One Boston Scientific Place
	Natick, MA 01780-1537
	508-650-8000
	www.bostonscientific.com

BOSTON SCIENTIFIC ANNOUNCES JURY VERDICT IN

PATENT LITIGATION WITH JOHNSON & JOHNSON

Natick, MA (June 21, 2005) -- Boston Scientific Corporation (NYSE: BSX) announced today that a jury in a patent infringement case in U.S. District Court in Delaware brought by Johnson & Johnson (NYSE: JNJ) against Boston Scientific has returned a verdict. The jury found that Boston Scientific’s TAXUS^® Express™, Express™, Express™ Biliary, and Liberté™ stents infringe a J&J patent and that the Liberté stent infringes a second J&J patent. Boston Scientific had challenged the validity of one of the patents, and the jury upheld the patent’s validity.

The jury only determined liability; monetary damages will be determined in a later trial. J&J is not seeking injunctive relief against the TAXUS Express, Express, or Express Biliary products. The Company stated that it is disappointed in the jury’s decision, and that there are likely to be significant post-verdict motions and hearings, as well as an appeal of the decision.

Boston Scientific is a worldwide developer, manufacturer, and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.

This press release contains forward-looking statements. The Company wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with litigation and other factors described in the Company’s filings with the Securities and Exchange Commission.

CONTACT:	Milan Kofol
	508-650-8569
	Investor Relations
	Boston Scientific Corporation
	Paul Donovan
	508-650-8541
	Media Relations
	Boston Scientific Corporation